Clinical safety of cardiovascular magnetic resonance: Cardiovascular devices and contrast agents

Hellenic Journal of Cardiology

Volumn 49, Issue 5, 2008, Pages 352-356

  Pamboucas, Constandinos A ^a,b   Rokas, Stylianos G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Cardiovascular devices; MR safety; Nephrogenic systemic fibrosis

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

AORTA GRAFT; CATHETER; CORONARY STENT; DEFIBRILLATOR; DRUG SAFETY; HEART VALVE PROSTHESIS; NUCLEAR MAGNETIC RESONANCE; PACEMAKER; REVIEW; RISK ASSESSMENT;

EID: 57349096021     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J. 2004; 25: 1940-1965.
2. Mavrogeni S, Rademakers F, Cokkinos D. Clinical application of cardiovascular magnetic resonance. Hellenic J Cardiol. 2004; 45: 401-405.
3. Sourides BE, Theofilogiannakos EK, Theofilogiannakos G, et al. Clinical experience from 1000 consecutive cardiovascular MRI cases at a tertiary referral medical center. Hellenic J Cardiol. 2007; 48: 192-197.
4. Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004; 232: 635-652.
5. Prasad SK, Pennell DJ. Safety of cardiovascular magnetic resonance in patients with cardiovascular implants and devices. Heart. 2004; 90: 1241-1244.
6. Pamboucas C, Nihoyannopoulos P. Cardiovascular magnetic resonance at 3 Tesla: advantages, limitations and clinical potential. Hellenic J Cardiol. 2006; 47: 170-173.
7. Shellock FG. Magnetic resonance safety update 2002: implants and devices. J Magn Reson Imaging. 2002; 16: 485-496.
8. Shellock FG. Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system. J Magn Reson Imaging. 2002; 16: 721-732.
9. Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: An American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention. Circulation. 2007; 116: 2878-2891.
10. Shellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla. J Cardiovasc Magn Reson. 2005; 7: 415-419.
11. Shellock FG. MR safety at 3-Tesla and coronary artery stents. MRIsafety.com. MRI safety, bioeffects and patient management [Internet]. 2008 [cited 2008 April 23]. Available from: http://www.mrisafety.com/safety_article. asp?subject=23
12. Porto I, Selvanayagam J, Ashar V, Neubauer S, Banning AP. Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation. Am J Cardiol. 2005; 96: 366-368.
13. Syed MA, Carlson K, Murphy M, Ingkanisorn WP, Rhoads KL, Arai AE. Long-term safety of cardiac magnetic resonance imaging performed in the first few days after bare-metal stent implantation. J Magn Reson Imaging. 2006; 24: 1056-1061.
14. Patel MR, Albert TS, Kandzari DE, et al. Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. Radiology. 2006; 240: 674-680.
15. Nijveldt R, Hirsch A, Hofman M, et al. 3.0 T cardiovascular magnetic resonance in patients treated with coronary stenting for myocardial infarction: evaluation of short term safety and image quality. Int J Cardiovasc Imaging. 2008; 24: 283-291.
16. Shinbane JS, Colletti PM, Shellock FG. MR in patients with pacemakers and ICDs: Defining the issues. J Cardiovasc Magn Reson. 2007; 9: 5-13.
17. Roguin A, Zviman MM, Meininger GR, et al. Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: In vitro and in vivo assessment of safety and function at 1.5 T. Circulation. 2004; 110: 475-482.
18. Martin ET, Coman JA, Shellock FG, Pulling CC, Fair R, Jenkins K. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll Cardiol. 2004; 43: 1315-1324.
19. Shellock FG, Fieno DS, Thomson TJ, Talavage TM, Berman DS. Cardiac pacemaker: in vitro assessment of MR safety at 1.5 Tesla. Am Heart J. 2006; 151: 436-443.
20. Nazarian S, Roguin A, Zviman MM, et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable cardioverter defibrillators at 1.5 Tesla. Circulation. 2006; 114: 1277-1284.
21. Sommer T, Naehle CP, Yang A, et al. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 Tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. Circulation. 2006; 114: 1285-1292.
22. Shellock FG, Fischer L, Fieno DS. Cardiac pacemakers and implantable cardioverter defibrillators: in vitro magnetic resonance imaging evaluation at 1.5 Tesla. J Cardiovasc Magn Reson. 2007; 9: 21-31.
23. Heatlie G, Pennell DJ. Cardiovascular magnetic resonance at 0.5 T in five patients with permanent pacemakers. J Cardiovasc Magn Reson. 2007; 9: 15-19.
24. Faris OP, Shein M. Food and Drug Administration perspective: magnetic resonance imaging of pacemaker and implantable cardioverter-defibrillator patients. Circulation. 2006; 114: 1232-1233.
25. Constantine G, Shan K, Flamm SG, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004; 363: 2162-2171.
26. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007; 2: 200-202.
27. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007; 242: 647-649.
28. Pamboucas C, Schmitz S, Nihoyannopoulos P. Magnetic resonance imaging in the detection of myocardial viability: the role of delayed contrast hyperenhancement. Hellenic J Cardiol. 2005; 46: 108-116.
29. Mavrogeni S, Giamouzis G, Pavlides G, Cokkinos DV. Grossly dilated vein graft evaluated by X-ray coronary angiography and contrast-enhanced magnetic resonance angiography. Hellenic J Cardiol. 2006; 47: 44-45.
30. Pamboucas C, Nihoyannopoulos P. Cardiovascular magnetic resonance for the assessment of pulmonary arterial hypertension. Hellenic J Cardiol. 2006; 47: 39-43.